-
Mashup Score: 2Anti-TIGIT therapies for solid tumors: a systematic review - 1 year(s) ago
Programmed death-ligand 1[PD-(L)1], cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3) inhibitors are recent breakthroughs in cancer treatment, however not all patients benefit from it. Thus new therapies are under investigation, such as anti-TIGIT [anti-T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif…
Source: Esmo OpenCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Lymphoma Daily - 2 year(s) ago
Content directly from sources and does not necessarily reflect my views by Jason R Westin
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest Lymphoma Daily! https://t.co/ar1ctmCbVc Thanks to @GarbineLizeaga @AJMC_Journal @EcoSenseNow #lymphoma #tigit
-
-
Mashup Score: 11Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials - 2 year(s) ago
In the immune-checkpoint era, the clinical course of advanced or metastatic non-small cell lung cancer (NSCLC) has remarkably improved. Treatment with immune checkpoint inhibitors (ICIs), namely anti-PD-1 and anti-PD-L1, has led to impressive long-term survival outcomes in EGFR/ALK wild type NSCLC, either as monotherapy (in the first-line setting for PD-L1 ≥ 50% tumors) or in combination with…
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Nice editorial @Annals_Oncology on #TIGIT by Drs. @IlariaAttiliMD @APassaroMD and Filippo De Marinis. Is targeting TIGIT and PD(L)1 enough or will we need to cover other components of the pathway? What is the biomarker? @OncoPolmoneIEO #LCSM https://t.co/LL83yqjGET
-
-
Mashup Score: 1CISH: A intracellular target for cancer immuno-therapy - 2 year(s) ago
This video provides, an overview of CISH, a gene found in humans and many other mammals that controls T cell receptor signaling. A member of a new class of i…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
Beyond PD-1 and immune checkpoint #TIGIT: intracellular checkpoint #CISH is unique for its ligand independence. #SITC21 Some info on our approach to targeting CISH @UMNCancer: https://t.co/tHV1wtRMEw https://t.co/DcQJ5zeEMP
-
-
Mashup Score: 1
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Answers coming as KEYMAKER U02 looking for combinations with #Lenvatanib , #TIGIT @angelesclinic https://t.co/tqsUZXylfZ #cancer #oncology #immunotherapy #clinicaltrials #phase1 https://t.co/Qdiuy0z6Uf
-
Review of #TIGIT online @ESMO_Open from Dr. @barlesi and team. Helpful overview of mechanism and anti-TIGIT molecules in development including tiragolumab, domvanalimab, vibostolimab, ociperlimab, EOS884448 and others. https://t.co/V6ZfkmwA8N